{"id":"W2159877301","doi":"10.1002/pbc.25454","title":"Re‐induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2","year":2015,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Chemoimmunotherapy; Induction chemotherapy; Chemotherapy; Oncology; Internal medicine; Regimen; Cog; Minimal residual disease; Chemotherapy regimen; Bone marrow; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009389917,0.0006658791,0.001188334,0.0006788013,0.0001793365,0.00005272046,0.0005084805,0.000524862,0.0001647877],"category_scores_gemma":[0.0004265326,0.0005444605,0.0001331884,0.001858312,0.0001858993,0.0002911508,0.0002343562,0.001146971,0.00006757312],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.005395134,"about_ca_system_score_gemma":0.007853901,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01375535,"about_ca_topic_score_gemma":0.001911361,"domain_scores_codex":[0.994448,0.0003250545,0.001162928,0.001478301,0.001477237,0.001108472],"domain_scores_gemma":[0.9967691,0.0004267449,0.0005581649,0.001171656,0.0004175086,0.0006568665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4060502,0.06993924,0.2571894,0.0003420269,0.02051339,0.01368643,0.07051914,0.002924411,0.01330842,0.00004524971,0.06956761,0.07591454],"study_design_scores_gemma":[0.7863778,0.07635996,0.1043469,0.0003612728,0.01620687,0.0008212223,0.004326968,0.00247389,0.001954997,0.0001444143,0.004315294,0.002310402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919411,0.002529905,0.00006411711,0.0009996356,0.0006430894,0.002695146,0.0002764937,0.0002215359,0.0006290019],"genre_scores_gemma":[0.9920357,0.001476956,0.001058265,0.0005594091,0.00284768,0.0007303451,0.0004261117,0.0001694953,0.0006959724],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3803276,"threshold_uncertainty_score":0.9997007,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02528339772203831,"score_gpt":0.3236444405717604,"score_spread":0.2983610428497221,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}